CORN REMOVAL

Main information

  • Trade name:
  • CORN REMOVAL
  • Dosage:
  • 40 %w/w
  • Pharmaceutical form:
  • Medicated Plaster
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • CORN REMOVAL
    Ireland
  • Language:
  • English

Status

  • Source:
  • HPRA - Health Products Regulatory Authority - Ireland
  • Authorization number:
  • PA0455/007/001
  • Authorization date:
  • 23-06-1987
  • Last update:
  • 14-10-2016

Summary of Product characteristics: dosage, interactions, side effects

IRISHMEDICINESBOARDACTS1995AND2006

MEDICINALPRODUCTS(CONTROLOFPLACINGONTHEMARKET)REGULATIONS,2007

(S.I.No.540of2007)

PA0455/007/001

CaseNo:2035414

TheIrishMedicinesBoardinexerciseofthepowersconferredonitbytheabovementionedRegulationsherebygrantsto

SchollConsumerProductsLimited

Venus,1OldParkLane,TraffordPark,ManchesterM417HA,UnitedKingdom

anauthorisation,subjecttotheprovisionsofthesaidRegulations,inrespectoftheproduct

CornRemovalMedicatedPlasters40%w/w

TheparticularsofwhicharesetoutinPartIandPartIIoftheattachedSchedule.Theauthorisationisalsosubjecttothegeneralconditionsas

maybespecifiedinthesaidRegulationsaslistedonthereverseofthisdocument.

Thisauthorisation,unlesspreviouslyrevoked,shallcontinueinforcefrom23/06/2007.

SignedonbehalfoftheIrishMedicinesBoardthis

________________

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 18/05/2010 CRN 2035414 page number: 1

PartII

SummaryofProductCharacteristics

1NAMEOFTHEMEDICINALPRODUCT

CornRemovalMedicatedPlasters40%w/w

2QUALITATIVEANDQUANTITATIVECOMPOSITION

Eachmedicatedplastercontainssalicylicacid40%w/w

Forafulllistofexcipients,seesection6.1.

3PHARMACEUTICALFORM

Medicatedplaster

Lightbrownplasterwithseparatedarkbrownsalicylicdisc.

4CLINICALPARTICULARS

4.1TherapeuticIndications

Forthetreatmentofcornsonthefeet.

4.2Posologyandmethodofadministration

Adults

Forthebestresultsthefeetshouldbewashedanddriedbeforeuse.Onemedicateddiscshouldbeplacedonthecorn,

coveredwithacoverplasterandsecuredwithastrap.Thisshouldberepeateddailyuntilthecorncanberemoved.

Treatmentshouldnotcontinueformorethantwoweeks.

Nodistinctionismadebetweendifferentcategoriesofpatient.

Children

Notrecommendedforchildrenunder16yearsofage,exceptfollowingadoctor’srecommendation.

4.3Contraindications

Nottobeusedbydiabeticsorthosewithseverecirculatorydisorders,exceptfollowingadoctor’spermissionand

recommendation.

Nottobeusedbythosesensitivetosalicylicacidoranyoftheotherconstituentsoftheproduct.

Nottobeusedifthecornorsurroundingskinisbrokenorinflamed.

Donotallowcontactwitheyes,mucosaorintactskin.

4.4Specialwarningsandprecautionsforuse

Discontinueuseandremoveplasterifexcessivediscomfortisexperienced.

Ifthereisaggravationoftheconditionornoimprovementthedoctorshouldbeconsulted.

Donotapplytonormalskin.

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 18/05/2010 CRN 2035414 page number: 2

4.5Interactionwithothermedicinalproductsandotherformsofinteraction

Notrelevanttocutaneoususe.

4.6Pregnancyandlactation

Safetyforuseinpregnancyandduringlactationhasnotbeenestablished.

4.7Effectsonabilitytodriveandusemachines

Nonestated.

4.8Undesirableeffects

Sideeffectsincludelocalirritationordermatitis.

4.9Overdose

Nonestated.

5PHARMACOLOGICALPROPERTIES

5.1Pharmacodynamicproperties

PharmacotherapeuticGroup:

Keratolytic.

MechanismofAction:

Themechanismofsalicylicacidhasnotbeenestablished.

PharmacodynamicEffects

Salicylateshaveanalgesic,anti-inflammatoryandantipyreticpropertiesmuchofwhichisascribedtoaninhibitionof

prostaglandinsynthesis.However,therelevantpharmacodynamiceffectofsalicylicacidforthisproductisits

“keratolytic”action.

Themechanismofthiseffecthasbeeninvestigatedinanimalsandinman,andappearstobeduetoalipidmodifying

effectinthelipidbilayersoftheskinratherthatakeratolyticaction.Itisthoughtthatthesalicylicacidincreaseslipid

structurefluiditysoallowingmoisturetopenetrateintoareassurroundingthecorn.Thisinturnleadstoapressure

buildupcausingthecorntobepushedupwards.Ithasbeensuggestedthattheocclusivenatureoftheplasterenhances

thiseffect.

5.2Pharmacokineticproperties

Salicylicacidcanbeabsorbedfollowingtopicalapplication.Plasmasalicylateislargelyprotein-boundandis

metabolisedbyoxidationandconjugationwithsomeexcretedunchanged.Theeliminationofsalicylatefollowsfirst

orderkineticswithahalflifeofaboutfourhoursexceptwithhighsystemicdoseswhichresultinsaturationofthe

eliminationmechanism.

5.3Preclinicalsafetydata

SalicylicacidhasalowacutetoxicitywithoralLD

valuesof480mg/kginthemouseand891mg/kgintherat.Itisa

dermalirritantbutsystemictoxicityfromapplicationof40%w/wsalicylicacidadhesivemassisextremelyunlikely

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 18/05/2010 CRN 2035414 page number: 3

6PHARMACEUTICALPARTICULARS

6.1Listofexcipients

PolyvinylAlkylEther(LowMolecularWeight)

PolyvinylAlkylEther(HighMolecularWeight)

TitaniumDioxide

LiquidParaffin

4,4’-Thio-Bis-2-Tert-Butyl-5-Methylphenol

RedIronOxide

BlackIronOxide

6.2Incompatibilities

Notapplicable.

6.3ShelfLife

Shelf-lifeinproductscontainingthemedicatedadhesivepackagedforsale

3years.

Shelf-lifeafterfirstopeningthecontainer

6weeks.

6.4Specialprecautionsforstorage

Donotstoreabove25 °

6.5Natureandcontentsofcontainer

Sachetcontents:

4medicatedadhesiveplastersmountedontoasiliconebackedpaper.

4coverPlastersmountedontoasiliconebackedpaper.

Outercontainer:

cardboardcartonorpolypropyleneflowwrap.

Notallpacksizesmaybemarketed.

6.6Specialprecautionsfordisposalofausedmedicinalproductorwastematerialsderivedfrom

suchmedicinalproductandotherhandlingoftheproduct

Nospecialrequirements.

7MARKETINGAUTHORISATIONHOLDER

SchollConsumerProductsLtd

Venus

1OldParkLane

TraffordPark

Manchester

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 18/05/2010 CRN 2035414 page number: 4

UnitedKingdom

8MARKETINGAUTHORISATIONNUMBER

PA455/7/1

9DATEOFFIRSTAUTHORISATION/RENEWALOFTHEAUTHORISATION

Dateoffirstauthorisation:23June1987

Dateoflastrenewal:23June2007

10DATEOFREVISIONOFTHETEXT

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 18/05/2010 CRN 2035414 page number: 5